KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to CalVista Pharmaceuticals 2025 Third Quarter Financial Update and Operating Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to your first speaker, Ryan Baker, Head of Investillations. Please go ahead. Thank you, Operator. Good morning, everyone, and thank you for joining us to discuss CalVista Pharmaceuticals' 2025 third quarter financial update and operating results. Please note we'll be making certain forward-looking statements today. We refer you to CalVista's SEC filings for discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today from CalVista are Ben Palayko, Chief Executive Officer, Nicole Sweeney, Chief Commercial Officer, Ryan Picos, Chief Financial Officer, and Dr. Paul Audia, our Chief Medical Officer. Ben will begin with a review of the company's progress during the three months ended September 30th, including an overview of Ectorly's early launch, both in the US and abroad, as well as other regulatory updates. Paul will give an update on recently presented data from our Confident Kid trial in HAE for children ages two to 11, as well as new patient satisfaction data. Nicole will review the company's commercial progress to date, and Ryan will cover the company's financial statements for the most recent quarter. We will then open the call for questions. With that, I will now turn the c...